Quick Answer
Entrada Therapeutics, Inc. reported Research And Development Expense of $142.27 million for the year ending 2025.
- Entrada Therapeutics, Inc. showed an increase of +13.5% in Research And Development Expense from 2024 to 2025.
- This data is from Entrada Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $5.70 million | Q1 2021: $6.22 million | Q2 2021: $6.83 million | Q3 2021: $10.51 million | Q1 2022: $15.72 million | Q2 2022: $16.25 million | Q3 2022: $18.96 million | Q1 2023: $23.10 million | Q2 2023: $26.30 million | Q3 2023: $22.19 million | Q1 2024: $28.61 million | Q2 2024: $32.04 million | Q3 2024: $31.26 million | Q1 2025: $32.07 million | Q2 2025: $37.88 million | Q3 2025: $38.36 million.
- Over the full 6 years of available data (2020 to 2025), Entrada Therapeutics, Inc.'s Research And Development Expense has grown by 574.2%.
- Historical annual values: Fiscal year 2025: $142.27 million | Fiscal year 2024: $125.31 million | Fiscal year 2023: $99.88 million | Fiscal year 2022: $66.61 million | Fiscal year 2021: $35.93 million | Fiscal year 2020: $21.10 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: